Oral Paclitaxel Combination Regimen Has Graduated In This Phase 2 Trial In The Triple-Negative Breast Cancer Subgroup
BUFFALO, NY, December 20, 2022 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced that Contributors to the Quantum Leap Healthcare Collaborative reported today that the company’s oral paclitaxel plus encequidar in combination with a PD-1 inhibitor and carboplatin has graduated to the triple-negative subset of high-risk early-stage breast cancer. Oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with increased febrile neutropenia. Quantum Leap Healthcare Collaborative plans to present these results at upcoming national meetings in the second quarter of 2023.
“We are very pleased that the Oral Paclitaxel combination regimen has graduated from this prestigious program that has brought exciting and innovative treatments to neoadjuvant breast cancer patients. This study confirms our finding of less neuropathy for oral paclitaxel compared to intravenous paclitaxel in our metastatic breast cancer study. It is reassuring to see that the oral paclitaxel regimen was not associated with an increase in febrile neutropenia compared with the intravenous paclitaxel regimen in a well-conducted US study,” said Dr. Johnson Lau, CEO of Athenex. “We will explore different opportunities to maximize the value of Oral Paclitaxel.”
About Quantum Leap Healthcare Collaborative
Quantum Leap Healthcare Collaborative is a 501c(3) charitable organization established in 2005 as a collaboration between medical researchers at the University of California, San Francisco and Silicon Valley entrepreneurs. Our mission is to integrate high-impact research with clinical processes and systems technology, resulting in better data management and information systems, greater access to clinical trial compliance and sponsorship, and greater benefit to providers, patients and researchers. Our goal is to improve and save lives. Quantum Leap provides operational, financial and regulatory oversight to I-SPY. For more information visit .
About I-SPY tests
The I-SPY TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2) (I-SPY 2 TRIAL) was designed to rapidly evaluate promising experimental treatments and identify the most effective ones in specific subgroups of patients based on of the molecular characteristics. (biomarker signatures). The trial is a unique collaborative effort by a consortium that includes the Food and Drug Administration (FDA), industry, patient advocates, philanthropic sponsors, and physicians from 16 of the leading US cancer research centers. Under the terms of the collaboration agreement, Quantum Leap Healthcare Collaborative is the trial sponsor and manages all study operations. For more information visit www.ispytrials.org.
About Athensex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next-generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex draws on years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The company’s current clinical portfolio is primarily derived from the following core technologies: (1) Cellular Therapy, based on NKT cells, and (2) Orascovery, based on a P-glycoprotein inhibitor. Athenex employees around the world dedicated to improving the lives of cancer patients by making treatments more active, accessible and tolerable. For more information please visit www.athenex.com.
Except for historical information, all statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements are generally identified by terms such as “explore”, “will”, “may”, “believe” and similar expressions. Actual results may differ materially from those expressed or implied in forward-looking statements. Important factors that could cause actual results to differ materially include: our history of operating losses and our need for and ability to raise additional capital to continue as a going concern; the stage of development of our lead clinical candidates and the related risks involved in drug development, clinical trials, regulation, uncertainties surrounding regulatory reviews and approvals, including further development of oral paclitaxel; preclinical and clinical results of Athenex drug candidates, which may not support further development of such drug candidates; the Company’s ability to successfully demonstrate the safety and efficacy of its drug candidates and obtain approval of its drug candidates in a timely manner, if at all; risks related to counterparty performance, including our reliance on third parties for success in certain areas of Athenex’s business; intellectual property risks and the other risk factors set forth from time to time in our filings with the SEC, copies of which are available free of charge on the Investor Relations section of our website at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or upon request to our Investor Relations Department. All information provided in this release is as of the date hereof, and we do not assume any obligation and do not intend to update these forward-looking statements, except as required by law.
Daniel Lang, MD Athenex, Inc. Email: [email protected]